Patents by Inventor Lorenz Studer
Lorenz Studer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11970712Abstract: The present invention relates to the field of stem cell biology, in particular the lineage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC) in addition to nonembryonic human induced pluripotent stem cells (hiPSC), somatic stem cells, stem cells from patients with a disease, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC into floor plate midbrain progenitor cells and then further into large populations of midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons using novel culture conditions.Type: GrantFiled: June 3, 2020Date of Patent: April 30, 2024Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Lorenz Studer, Jae-Won Shim, Sonja Kriks
-
Patent number: 11959104Abstract: The presently disclosed subject matter provides for in vitro methods of inducing differentiation of human stem cells into neural crest, cranial placode or non-neuro ectoderm precursors, and cells generated by such methods. The presently disclosed subject matter also provides for uses of such cells for treating neurodegenerative and pituitary disorders.Type: GrantFiled: April 4, 2022Date of Patent: April 16, 2024Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Lorenz Studer, Bastian Zimmer, Jason Tchieu
-
Publication number: 20240067924Abstract: Cranial placodes are embryonic structures essential for sensory and endocrine organ development. The efficient derivation of cranial placodes from human pluripotent stem cells is disclosed where the timed removal of the BMP inhibitor Noggin, a component of the dual-SMAD inhibition strategy of neural induction, triggers placode induction at the expense of CNS fates. Further fate specification at the pre-placode stage enables the selective generation of placode-derived trigeminal ganglia capable of in vivo engraftment, mature lens fibers and anterior pituitary hormone-producing cells that upon transplantation produce hormones including, but not limited to, human growth hormone and adrenocortiocotropic hormone in vivo. Alternatively, anterior pituitary hormone-producing cells are generated in cell culture systems in vitro.Type: ApplicationFiled: December 21, 2022Publication date: February 29, 2024Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Stuart Chambers, Lorenz Studer, Zehra Dincer, Bastian Zimmer
-
Publication number: 20240050486Abstract: The present disclosure provides methods for generating cortical excitatory neurons, cortical excitatory neurons generated by such methods, and composition comprising such cells. The present disclosure also provides uses of the cortical excitatory neurons and composition comprising thereof for preventing and/or treating neurodegenerative disorders.Type: ApplicationFiled: July 7, 2023Publication date: February 15, 2024Applicants: Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute for Cancer Research, Memorial Hospital for Cancer and Allied DiseasesInventors: Lorenz Studer, Gabriele CICERI
-
Publication number: 20230365928Abstract: Provided are cortical interneurons and other neuronal cells and in vitro methods for producing such cortical interneurons and other neuronal cells by the directed differentiation of stem cells and neuronal progenitor cells. The present disclosure relates to novel methods of in vitro differentiation of stem cells and neural progenitor cells to produce several type neuronal cells and their precursor cells, including cortical interneurons, hypothalamic neurons and pre-optic cholinergic neurons. The present disclosure describes the derivation of these cells via inhibiting SMAD and Wnt signaling pathways and activating SHH signaling pathway. The present disclosure relates to the novel discovery that the timing and duration of SHH activation can be harnessed to direct controlled differentiation of neural progenitor cells into either cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons.Type: ApplicationFiled: April 6, 2023Publication date: November 16, 2023Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, CORNELL UNIVERSITYInventors: Lorenz Studer, Asif M. Maroof, Stewart Anderson
-
Publication number: 20230323294Abstract: The presently disclosed subject matter provides for in vitro methods of inducing differentiation of human stem cells into cortical neurons, and cortical neurons generated by such methods. The presently disclosed subject matter also provides for uses of such cortical neurons for treating neurodegenerative CNS disorders.Type: ApplicationFiled: May 30, 2023Publication date: October 12, 2023Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Yuchen Qi, Lorenz Studer
-
Patent number: 11754551Abstract: Disclosed herein are methods and compositions for identifying transcriptional and epigenetic age-related markers. Disclosed herein are also methods and compositions for reprogramming cell age by modulating transcriptional and epigenetic age-related markers identified herein. The identified transcriptional and epigenetic age-related markers can also be used for measuring cellular age in a cell or tissue.Type: GrantFiled: August 9, 2019Date of Patent: September 12, 2023Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Lorenz Studer, Daniela Cornacchia
-
Publication number: 20230220335Abstract: The present invention relates generally to the field of cell biology of stem cells, more specifically the directed differentiation of pluripotent or multipotent stem cells, including human embryonic stem cells (hESC), somatic stem cells, and induced human pluripotent stem cells (hiPSC) using novel culture conditions. Specifically, methods are provided for obtaining neural tissue, floor plate cells, and placode including induction of neural plate development in hESCs for obtaining midbrain dopamine (DA) neurons, motor neurons, and sensory neurons. Further, neural plate tissue obtained using methods of the present inventions are contemplated for use in co-cultures with other tissues as inducers for shifting differentiation pathways, i.e. patterning.Type: ApplicationFiled: January 11, 2023Publication date: July 13, 2023Applicant: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Stuart Chambers, Lorenz Studer
-
Patent number: 11649431Abstract: Provided are cortical interneurons and other neuronal cells and in vitro methods for producing such cortical interneurons and other neuronal cells by the directed differentiation of stem cells and neuronal progenitor cells. The present disclosure relates to novel methods of in vitro differentiation of stem cells and neural progenitor cells to produce several type neuronal cells and their precursor cells, including cortical interneurons, hypothalamic neurons and pre-optic cholinergic neurons. The present disclose describes the derivation of these cells via inhibiting SMAD and Wnt signaling pathways and activating SHH signaling pathway. The present disclosure relates to the novel discovery that the timing and duration of SHH activation can be harnessed to direct controlled differentiation of neural progenitor cells into either cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons.Type: GrantFiled: October 23, 2015Date of Patent: May 16, 2023Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, CORNELL UNIVERSITYInventors: Lorenz Studer, Asif M. Maroof, Stewart Anderson
-
Publication number: 20230143486Abstract: The present disclosure provides methods for generating midbrain dopamine neurons and precursors thereof, midbrain dopamine neurons and precursors thereof generated by such methods and compositions comprising such cells, and uses thereof for preventing, modeling, and/or treating a neurological disorder.Type: ApplicationFiled: September 30, 2022Publication date: May 11, 2023Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Lorenz STUDER, Tae-Wan KIM, So-Yeon KOO
-
Patent number: 11591567Abstract: Cranial placodes are embryonic structures essential for sensory and endocrine organ development. The efficient derivation of cranial placodes from human pluripotent stem cells is disclosed where the timed removal of the BMP inhibitor Noggin, a component of the dual-SMAD inhibition strategy of neural induction, triggers placode induction at the expense of CNS fates. Further fate specification at the pre-placode stage enables the selective generation of placode-derived trigeminal ganglia capable of in vivo engraftment, mature lens fibers and anterior pituitary hormone-producing cells that upon transplantation produce hormones including, but not limited to, human growth hormone and adrenocortiocotropic hormone in vivo. Alternatively, anterior pituitary hormone-producing cells are generated in cell culture systems in vitro.Type: GrantFiled: April 2, 2019Date of Patent: February 28, 2023Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Stuart Chambers, Lorenz Studer, Zehra Dincer, Bastian Zimmer
-
Patent number: 11560546Abstract: The present invention relates generally to the field of cell biology of stem cells, more specifically the directed differentiation of pluripotent or multipotent stem cells, including human embryonic stem cells (hESC), somatic stem cells, and induced human pluripotent stem cells (hiPSC) using novel culture conditions. Specifically, methods are provided for obtaining neural tissue, floor plate cells, and placode including induction of neural plate development in hESCs for obtaining midbrain dopamine (DA) neurons, motor neurons, and sensory neurons. Further, neural plate tissue obtained using methods of the present inventions are contemplated for use in co-cultures with other tissues as inducers for shifting differentiation pathways, i.e. patterning.Type: GrantFiled: February 20, 2019Date of Patent: January 24, 2023Assignee: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Stuart Chambers, Lorenz Studer
-
Patent number: 11542470Abstract: The presently disclosed subject matter provides for in vitro methods of inducing differentiation of stem cells (e.g., human stem cells) into proprioceptors, proprioceptors generated by such methods, and compositions comprising such proprioceptors. The presently disclosed subject matter also provides for uses of such proprioceptors for preventing and/or treating disorders of proprioceptor neurons and/or neurodegenerative disorders (e.g., Friedreich's Ataxia).Type: GrantFiled: November 26, 2018Date of Patent: January 3, 2023Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Lorenz Studer, Nadja Zeltner
-
Publication number: 20220228123Abstract: The presently disclosed subject matter provides for in vitro methods of inducing differentiation of human stem cells into neural crest, cranial placode or non-neuro ectoderm precursors, and cells generated by such methods. The presently disclosed subject matter also provides for uses of such cells for treating neurodegenerative and pituitary disorders.Type: ApplicationFiled: April 4, 2022Publication date: July 21, 2022Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Lorenz STUDER, Bastian ZIMMER, Jason TCHIEU
-
Publication number: 20220186180Abstract: The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC), human induced pluripotent stem cells (hiPSC), somatic stem cells, cancer stem cells, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC to nociceptors (i.e. nociceptor cells) using novel culture conditions. The nociceptors made using the methods of the present invention are further contemplated for various uses including, but limited to, use in in vitro drug discovery assays, pain research, and as a therapeutic to reverse disease of, or damage to, the peripheral nervous system (PNS). Further, compositions and methods are provided for producing melanocytes from human pluripotent stem cells for use in disease modeling.Type: ApplicationFiled: December 22, 2021Publication date: June 16, 2022Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Lorenz Studer, Stuart M. Chambers, Yuchen Qi, Yvonne Marissa Mica
-
Publication number: 20220177835Abstract: The present disclosure provides methods for generating midbrain dopamine neurons (mDAs) and precursors thereof, mDAs and precursors thereof generated by such methods and compositions comprising such cells, and uses thereof for preventing and/or treating neurological disorders. The present disclosure further provides methods of isolating mDAs and precursors thereof from a cell population using novel surface markers.Type: ApplicationFiled: February 25, 2022Publication date: June 9, 2022Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Lorenz Studer, Taewan Kim, Stefan Irion, So Yeon Koo
-
Patent number: 11326148Abstract: The presently disclosed subject matter provides for in vitro methods of inducing differentiation of human stem cells into neural crest, cranial placode or non-neuro ectoderm precursors, and cells generated by such methods. The presently disclosed subject matter also provides for uses of such cells for treating neurodegenerative and pituitary disorders.Type: GrantFiled: August 3, 2018Date of Patent: May 10, 2022Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Lorenz Studer, Bastian Zimmer, Jason Tchieu
-
Publication number: 20210332436Abstract: The present disclosure relates to pluripotent stem cell (e.g., human PSC) based multiplex methods and compositions for identifying genes associated with the pathogenesis of a disorder (e.g., human disorder) and the responsiveness to certain treatments to such disorder. The present disclosure also provides genetic markers for identifying clinically relevant subpopulations of autism patients.Type: ApplicationFiled: May 13, 2021Publication date: October 28, 2021Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Lorenz Studer, Gustav Cederquist
-
Publication number: 20210214681Abstract: The present disclosure relates to methods for generating microglial cells derived from stem cells (e.g., human stem cells), microglial cells obtained from such methods and compositions comprising thereof, and uses of said microglial cells for disease modeling and for treating microglia related disorders.Type: ApplicationFiled: March 26, 2021Publication date: July 15, 2021Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Lorenz Studer, Sudha Ragavalli Guttikonda
-
Publication number: 20210123018Abstract: The presently disclosed subject matter provides for in vitro methods of inducing differentiation of human stem cells into midbrain dopamine neurons, and precursors thereof, and cells generated by such methods. The presently disclosed subject matter also provides for uses of such cells for treating neurodegenerative disorders.Type: ApplicationFiled: November 9, 2020Publication date: April 29, 2021Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Lorenz Studer, Stefan Irion, Mark Tomishima, Sonja Kriks